Compass Pathways plc
CMPSDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
CMPS Earnings Report
EPS Est: $-0.46 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How CMPS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Psilocybin | Phase 3 | Treatment Resistant Depression | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Compass Pathways plc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Compass Pathways plc's (CMPS) pipeline across Phase 3. Its lead program is Psilocybin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compass Pathways plc's next FDA catalyst?→
Compass Pathways plc's (CMPS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CMPS biotech catalysts?→
Add CMPS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compass Pathways plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.